Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
about
Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclaseHIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaquesCellular normoxic biophysical markers of hydroxyurea treatment in sickle cell diseaseSustained delivery of erythropoietin in mice by genetically modified skin fibroblastsSustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo.Darbepoetin-alpha: a review of the literature.Bone marrow transplant for sickle cell disease--an updateThe role of hydroxyurea in sickle cell disease.Pharmacologic induction of fetal hemoglobin synthesis: cellular and molecular mechanisms.Pharmacotherapy in sickle cell disease--state of the art and future prospectsGum Arabic as fetal hemoglobin inducing agent in sickle cell anemia; in vivo study.Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations.Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature reviewImpaired deformability of circulating erythrocytes obtained from nondiabetic hypertensive patients: investigation by a nickel mesh filtration technique.CNTO 530 increases expression of HbA and HbF in murine models of β-thalassemia and sickle cell anemia.Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: Strategies to treat sickle cell diseaseTranscriptional mechanisms underlying hemoglobin synthesis.Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for Identification of Drugs for the Treatment of {beta}-Thalassemia and Sickle-Cell Anemia.Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease.Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.Management of the Dialysis Patient with Sickle Cell Disease.A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.In sickle disease, unlike wine, dry is not goodA new therapeutic approach for sickle cell disease. Blockade of the red cell Ca(2+)-activated K+ channel by clotrimazole.Hydroxyurea stimulates the release of ATP from rabbit erythrocytes through an increase in calcium and nitric oxide production.The use of haemopoietic growth factors in blood disorders.Rapamycin-mediated induction of gamma-globin mRNA accumulation in human erythroid cells.Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine.Improvement of mouse beta-thalassemia upon erythropoietin delivery by encapsulated myoblasts.Novel treatment options in the severe beta-globin disorders.The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells.A Hydroxyurea-induced Leg Ulcer.Utrophin: a structural and functional comparison to dystrophin.Growth factors and their impact on transfusion medicine.The management of sickle cell disease in a primary care setting.Current therapy of sickle cell disease.Accumulation of gamma-globin mRNA in human erythroid cells treated with angelicin.Novel approaches to treatment of sickle cell anaemia.
P2860
Q24554376-7A43C918-62D0-418D-A03C-868ED8B64492Q24684076-E9F5594B-4454-4C8D-8E5C-6CAEE96A8F88Q28828635-2CC3C81D-4D50-4554-A9ED-6083C2D8CC47Q34421635-D41950B8-84A4-4CC6-B3AD-31254CDFC90BQ34723434-3A53E5B0-8709-4071-90D7-94AD71F274F4Q34723868-A31EF95D-4EB9-402B-80BB-C68ED187744AQ34748838-B1D15C26-8919-4D2E-8CC8-B6A7956C5B0BQ34799417-F098BF91-AE08-4AA9-B879-6186B22083E7Q35050928-67772334-CD68-410A-B8DE-1FCF153454BAQ35098104-0085AAA8-BFD9-4F53-B2DE-72F0A80566AAQ35220342-6517FE9D-D19C-4279-BCFF-FE0B99C90F58Q35882386-5BD7E091-A6C7-40D1-9ACA-BDB4A8F71D98Q36333394-1D86F49F-EE8C-4869-95BA-E2EF4E68359CQ36467377-7AB27DC9-E119-4CC0-BB6F-4C8EC42F3F97Q36572318-DC6589FE-36B6-45D0-A4AB-B51D349751D5Q36733103-5533BE39-6628-4E98-B438-D577453326A0Q37071189-E0E47E90-AC63-44DF-B0B8-93062E3B1935Q37122360-6A1B8864-6CB5-4658-911D-FAD5EB0C0E48Q37309900-113CE0B5-E52C-45A8-A915-AEEFF907F9D7Q37352493-C2FE5EDF-A518-4A98-8B67-F6A09B9BD358Q37524864-BBE14BE4-584B-41A4-81E5-EE445BE795ACQ38025159-A6C8CADD-30D6-42EE-B08F-67DDC269B5BDQ38547177-D78EF18F-262A-435D-A1BF-4961AB67C384Q39390596-D75CDAF4-F9FD-4B0A-A3CF-7CAB97F6D824Q40332411-8838A3B2-C6BD-44A0-B284-599CD5B3C839Q40483920-10602807-4A9A-4088-9C47-5D5F07C077A2Q40506406-21FF18B4-1983-45F1-82B1-21AB8DC0E449Q40511423-C5E51978-127A-485B-AE90-D6525A128A04Q40529667-9958C55A-D794-46E9-AA61-EB921E42777EQ40794098-A269B2E6-D3E0-48A6-8583-476D82F94708Q40937517-D8BC80C8-6B0C-4CBE-94F0-777FC96D6C52Q40938157-B14D0020-8E82-4EC7-AC4F-342A485876B7Q40970099-321C3E0D-755A-4A35-B15A-24156173B0FDQ40970728-86CA2209-55E5-4BCA-BAC5-A8404169B03AQ41160197-9D58D1B4-EA53-4D07-BA40-F401C8B4A5EAQ41261188-0C32F214-DE82-4CA3-8038-D456D7231D2EQ41875605-E00C0D66-47C7-46BA-9122-611AE0A77815Q42959583-74FD2F6B-3E00-4C24-954C-19C9FAF638BAQ44557344-21914647-E008-415F-A2D7-FF33DC420433Q45873795-A0EBF567-7B58-455C-A6DF-7D6692137BA8
P2860
Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
description
1993 nî lūn-bûn
@nan
1993 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Augmentation by erythropoietin ...... xyurea in sickle cell disease.
@ast
Augmentation by erythropoietin ...... xyurea in sickle cell disease.
@en
Augmentation by erythropoietin ...... xyurea in sickle cell disease.
@nl
type
label
Augmentation by erythropoietin ...... xyurea in sickle cell disease.
@ast
Augmentation by erythropoietin ...... xyurea in sickle cell disease.
@en
Augmentation by erythropoietin ...... xyurea in sickle cell disease.
@nl
prefLabel
Augmentation by erythropoietin ...... xyurea in sickle cell disease.
@ast
Augmentation by erythropoietin ...... xyurea in sickle cell disease.
@en
Augmentation by erythropoietin ...... xyurea in sickle cell disease.
@nl
P2093
P1476
Augmentation by erythropoietin ...... xyurea in sickle cell disease.
@en
P2093
Nienhuis AW
Noguchi CT
Rodgers GP
Schechter AN
P356
10.1056/NEJM199301143280201
P407
P577
1993-01-01T00:00:00Z